Clinical Trial: Prostaglandin E2 Predicts the Outcome of Acute-on-chronic Liver Failure

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational




Official Title: A Study on Prostaglandin E2 Predicting the Outcome of Acute-on-chronic Liver Failure

Brief Summary: Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).